探索归巢至胶质母细胞瘤的干细胞：应时而起。

To Explore the Stem Cells Homing to GBM: The Rise to the Occasion.

作者信息

Tsibulnikov Sergey, Drefs Natalya M, Timashev Peter S, Ulasov Ilya V

机构信息

Group of Experimental Biotherapy and Diagnostic, Institute for Regenerative Medicine, Sechenov First Moscow State Medical University, Trubetskaya 8-2, 119991 Moscow, Russia.

TS Oncology, 125047 Moscow, Russia.

出版信息

Biomedicines. 2022 Apr 24;10(5):986. doi: 10.3390/biomedicines10050986.

DOI:10.3390/biomedicines10050986

PMID:35625723

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9138893/

Abstract

Multiple efforts are currently underway to develop targeted therapeutic deliveries to the site of glioblastoma progression. The use of carriers represents advancement in the delivery of various therapeutic agents as a new approach in neuro-oncology. Mesenchymal stem cells (MSCs) and neural stem cells (NSCs) are used because of their capability in migrating and delivering therapeutic payloads to tumors. Two of the main properties that carrier cells should possess are their ability to specifically migrate from the bloodstream and low immunogenicity. In this article, we also compared the morphological and molecular features of each type of stem cell that underlie their migration capacity to glioblastoma. Thus, the major focus of the current review is on proteins and lipid molecules that are released by GBM to attract stem cells.

摘要

目前正在进行多项努力，以开发针对胶质母细胞瘤进展部位的靶向治疗递送方法。载体的使用代表了在递送各种治疗剂方面的进步，这是神经肿瘤学中的一种新方法。间充质干细胞（MSCs）和神经干细胞（NSCs）因其具有迁移并向肿瘤递送治疗载荷的能力而被使用。载体细胞应具备的两个主要特性是它们从血液中特异性迁移的能力和低免疫原性。在本文中，我们还比较了每种类型干细胞的形态和分子特征，这些特征是它们向胶质母细胞瘤迁移能力的基础。因此，当前综述的主要重点是胶质母细胞瘤释放的吸引干细胞的蛋白质和脂质分子。